If you’re using ChatGPT and it helps you discover a new drug... OpenAI may take a cut.

OpenAI’s CFO recently said her company could take a “license to the drug that is discovered” using ChatGPT. Essentially, OpenAI would take a profit-sharing stake in the financial upside its AI creates for customers.

To be fair, OpenAI isn’t the only one thinking about doing this. According to The Information, rivals like Anthropic, Google DeepMind, and Isomorphic Labs are also focusing on using AI for drug discovery and holding discussions about data licensing and partnerships. 

Thoughts on this business model? Let me know below.👇

#OpenAI #AI #Biotech #technews

Matt Wolfe

OpenAI plans to take a cut of AI-aided drug discoveries made using their models through licensing agreements and outcome-based pricing. The CFO stated the company could license drugs discovered with their AI. Competitors like Anthropic, Google DeepMind, and Isomorphic Labs are also exploring similar arrangements with biotech startups for data licensing and partnerships in AI-driven drug discovery.

OpenAI Wants A Cut Of ChatGPT Drug Discoveries